Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 66.09% is 832% above its 5-year average of -9.02%, near the high end of its 5-year range (-22196.21%–100.00%).
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 0.00%.
GROSS MARGIN
66.09%
GROSS MARGIN AVG TTM
0.00%
GROSS MARGIN AVG 3Y
0.00%
GROSS MARGIN AVG 5Y
-9.02%
GROSS MARGIN AVG 10Y
-9.31%
GROSS MARGIN AVG 15Y
30.82%
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
+832.48%
CURRENT VS 10Y AVG
+809.63%
CURRENT VS 15Y AVG
+114.46%
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
41.38%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
+59.71%
vs the sector median at left
Xenon Pharmaceuticals Inc.
Market Cap
$3.52B
Gross Margin
66.09%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
-9.02%
Market Cap
$3.53B
Gross Margin
71.45%
TTM Avg
69.72%
3Y Avg
68.83%
5Y Avg
69.16%
Market Cap
$3.48B
Gross Margin
-43.89%
TTM Avg
0.67%
3Y Avg
45.02%
5Y Avg
61.14%
Market Cap
$3.57B
Gross Margin
98.25%
TTM Avg
98.17%
3Y Avg
99.09%
5Y Avg
95.85%
Market Cap
$3.43B
Gross Margin
-360.00%
TTM Avg
-180.00%
3Y Avg
-491.57%
5Y Avg
-334.18%
Market Cap
$3.65B
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$3.38B
Gross Margin
91.13%
TTM Avg
91.57%
3Y Avg
93.72%
5Y Avg
94.38%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Xenon Pharmaceuticals Inc. (XENE) | $3.52B | 66.09% | 0.00% | 0.00% | -9.02% |
| iRhythm Technologies, Inc. (IRTC)vs › | $3.53B | 71.45% | 69.72% | 68.83% | 69.16% |
| Veracyte, Inc. (VCYT)vs › | $3.55B | 72.09% | 68.25% | 67.74% | 66.97% |
| Celcuity Inc. (CELC)vs › | $3.47B | 0.00% | 0.00% | 0.00% | 0.00% |
| IDEAYA Biosciences, Inc. (IDYA)vs › | $3.48B | -43.89% | 0.67% | 45.02% | 61.14% |
| Tango Therapeutics, Inc. (TNGX)vs › | $3.57B | 98.25% | 98.17% | 99.09% | 95.85% |
| Pulse Biosciences, Inc. (PLSE)vs › | $3.43B | -360.00% | -180.00% | -491.57% | -334.18% |
| Regencell Bioscience Holdings Limited (RGC)vs › | $3.65B | 0.00% | 0.00% | 0.00% | 0.00% |
| Acadia Pharmaceuticals Inc. (ACAD)vs › | $3.38B | 91.13% | 91.57% | 93.72% | 94.38% |
| Parabilis Medicines, Inc. (PBLS)vs › | $3.37B | 0.00% | 0.00% | 0.00% | 0.00% |
Gross Margin
66.1%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 0.00% |
| 2026-03-31 | 0.00% |
| 2025-12-31 | 0.00% |
| 2025-09-30 | 0.00% |
| 2025-06-30 | 0.00% |
| 2025-03-31 | 100.00% |
| 2024-12-31 | 0.00% |
| 2024-09-30 | 0.00% |
| 2024-06-30 | 0.00% |
| 2024-03-31 | 0.00% |
| 2023-12-31 | 0.00% |
| 2023-09-30 | 0.00% |
| 2023-06-30 | 0.00% |
| 2023-03-31 | 0.00% |
| 2022-12-31 | 0.00% |
| 2022-09-30 | -22196.21% |
| 2022-06-30 | -4031.72% |
| 2022-03-31 | -120.85% |
| 2021-12-31 | -485.68% |
| 2021-09-30 | -132.53% |
| 2021-06-30 | -728.54% |
| 2021-03-31 | -274.21% |
| 2020-12-31 | -190.62% |
| 2020-09-30 | 100.00% |
| 2020-06-30 | 100.00% |
| 2020-03-31 | 100.00% |
| 2019-12-31 | 100.00% |
| 2019-09-30 | -178.60% |
| 2019-06-30 | 0.00% |
| 2019-03-31 | 0.00% |
| 2018-12-31 | -6.70% |
| 2018-09-30 | 0.00% |
| 2018-06-30 | 0.00% |
| 2018-03-31 | 0.00% |
| 2017-12-31 | -39881.25% |
| 2017-09-30 | -2613.64% |
| 2017-06-30 | -40626.67% |
| 2017-03-31 | -36793.75% |
| 2016-12-31 | 97.87% |
| 2016-09-30 | -18.89% |
| 2016-06-30 | 17.19% |
| 2016-03-31 | 51.91% |
| 2015-12-31 | 82.40% |
| 2015-09-30 | 85.51% |
| 2015-06-30 | 82.48% |
| 2015-03-31 | 78.48% |
| 2014-12-31 | 78.72% |
| 2014-09-30 | 86.66% |
| 2014-06-30 | 69.25% |
| 2014-03-31 | 70.49% |
| 2013-12-31 | 67.65% |
| 2013-09-30 | 86.33% |
| 2013-06-30 | 73.34% |
| 2013-03-31 | 73.34% |
| 2012-12-31 | 32.04% |
| 2012-09-30 | 32.04% |
